Pharmacological management in children and adolescents with pervasive developmental disorder

Australian and New Zealand Journal of Psychiatry

Volumn 44, Issue 5, 2010, Pages 410-428

  Sung, Min ^a   Fung, Daniel S S ^a   Cai, Yiming ^a   Ooi, Yoon Phaik ^b  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b Child Guidance Clinic   (Singapore)

Author keywords

Asperger's syndrome; Autism; Autism spectrum disorder; Pervasive developmental disorder; Pharmacological management

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; LITHIUM CARBONATE; MELATONIN; MEMANTINE; METHYLPHENIDATE; NALTREXONE; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; VALPROATE SEMISODIUM; ZIPRASIDONE; PSYCHOTROPIC AGENT;

ADOLESCENT; AGGRESSION; AGITATION; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BEHAVIOR DISORDER; BODY WEIGHT; CHILD; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DATA BASE; DECREASED APPETITE; DIAPHORESIS; DROWSINESS; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIC DISORDER; ENURESIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERACTIVITY; HYPERTENSION; IMPULSIVENESS; INCREASED APPETITE; INFANTILE AUTISM; INSOMNIA; IRRITABILITY; LETHARGY; LOW DRUG DOSE; MEDLINE; MENTAL CONCENTRATION; NAUSEA; PHYSICAL ACTIVITY; PSYARTICLE; PSYCHOSOCIAL WITHDRAWAL; PSYCINFO; RESTLESSNESS; RITUAL; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TACHYCARDIA; TREMOR; URINE RETENTION; VIVID DREAM; WEIGHT GAIN; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; DRUG EFFECTS; FEMALE; MALE; META ANALYSIS; PSYCHOLOGY; PSYCHOMOTOR AGITATION; SELF-INJURIOUS BEHAVIOR; STEREOTYPY; TREATMENT OUTCOME;

ADOLESCENT; AGGRESSION; ANXIETY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; FEMALE; HUMANS; IRRITABLE MOOD; MALE; PSYCHOMOTOR AGITATION; PSYCHOTROPIC DRUGS; SELF-INJURIOUS BEHAVIOR; STEREOTYPED BEHAVIOR; TREATMENT OUTCOME;

EID: 77951261852     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048670903493330     Document Type: Article

References (79)

1. Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of literature. Res Dev Disabil 2006; 27:254-289.
2. McDougle CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry 2005; 66:9-18.
3. Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 2002; 52:805-810.
4. Volkmar F, Cook EH Jr, Pomeroy J, Realmuto G, Tanguay P. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 1999; 38 (Suppl 12):32-54.
5. Santosh PS, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. Lancet 1999; 354:233-242. (Pubitemid 29329171)
6. Gordon CT, State RC, Nelson JE. A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50:441-447. (Pubitemid 23169937)
7. Remington G, Sloman L, Konstantareas M e t al. Clomipramine vs haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled crossover study. J Clin Psychopharmacol 2001; 21:440-444. (Pubitemid 32673034)
8. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996; 35:537-544. (Pubitemid 126418618)
9. McDougle CJ, Naylor ST, Cohen DJ et al. Double-blind, placebocontrolled study of fl uvoxamine in adults with autistic disorders. Arch Gen Psychiatry 1996; 53:1001-1008.
10. McDougle CJ, Kresch LB, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disabil 2000; 30:427-435.
11. Martin A, Koenig K, Anderson GM. Low-dose fl uvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Autism Dev Disord 2003; 33:77-85. (Pubitemid 36323142)
12. Hollander E, Phillips A, Chaplin W et al. A placebo-controlled crossover trial of liquid fl uoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005; 30:582-589. (Pubitemid 40271160)
13. Fatemi SH, Realmuto GM, Khan L, Thuras P. Fluoxetine in the treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998; 28:303-307. (Pubitemid 28368957)
14. DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002; 44:652-659. (Pubitemid 35230025)
15. Cook EH, Rowlett R, Jaselinkis C. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31:739-745.
16. Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003; 24:104-108. (Pubitemid 36546777)
17. Owley T, Walton L, Salt J et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005; 44:343-348. (Pubitemid 40393272)
18. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective, open-label investigation. J Clin Psychopharmacol 1998; 18:62-66.
19. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996; 57:333-336. (Pubitemid 26277885)
20. Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997; 7:9-15. (Pubitemid 27252846)
21. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic related dyskinesias in autistic children: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36:835-843. (Pubitemid 27250449)
22. Campbell M, Anderson LT, Small AM, Perry R, Green WH, Caplan R. The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord 1982; 12:167-175. (Pubitemid 12018684)
23. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms on autistic children. J Autism Dev Disord 1989; 19:227-239. (Pubitemid 19176531)
24. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl):1-93. (Pubitemid 40677047)
25. McCracken JT, McGough J, Shah B e t al. Risperidone in children with autism and serious behavioral problems. New Engl J Med 2002; 347:314-321. (Pubitemid 34815353)
26. McDougle CJ, Scahill L, Aman MG e t al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162:1142-1148. (Pubitemid 40770697)
27. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone treatment of autistic disorder: longer-term benefi ts and blinded discontinuation after 6 months. Am J Psychiatry 2005; 162:1361-1369.
28. Shea S, Turgay A, Carroll A e t al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatr 2004; 114: 634-641. (Pubitemid 41647671)
29. Potenza MN, Holmes JP, Kanes SJ. Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999; 19:37-44.
30. Kemner C, Wilemsen-Swinkels SH, de Jonge M. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22:455-460.
31. Malone RP, Cate J, Sheikh RM. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40:887-894.
32. Hollander E, Wasserman S, Swanson EN. A double-blind placebocontrolled pilot study of olanzapine in childhood adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16:541-548. (Pubitemid 44737209)
33. Martin A, Koenig K, Scahill L. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9:99-107. (Pubitemid 29379846)
34. Findling RL, McNamara NK, Gracious BL. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14:287-294.
35. Corson AH, Barkenbus JE, Posey DJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004; 65:1531-1536.
36. Hardan AY, Jou RJ, Handan BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 2005; 35:387-391. (Pubitemid 41125976)
37. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41:921-927.
38. Cohen SA, Fitzgerald BJ, Khan SR, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 2004; 65:110-113.
39. Food and Drug Administration. (FDA) Psychopharmacological Drugs Advisory Committee background document on Zeldox (PDAC 0700.M01). Rockville, MD: Food and Drug Administration; 2000.
40. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychiatry 2002; 41:921-927.
41. Stigler KA, Diener JT, Kohn AE, Erickson CA, Posey DJ, McDougle CJ. A prospective, open-label study of aripiprazole in youth with pervasive developmental disorder not otherwise specifi ed and Asperger's disorder. J Child Adolesc Psychopharmacol 2009 Jun; 19(3): 265-274
42. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006; 16:549-560. (Pubitemid 44737210)
43. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996; 153:738. (Pubitemid 26133642)
44. Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 2001; 62:479-480. (Pubitemid 32717889)
45. Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. J Psychiatry Neurosci 2001; 26:340-341. (Pubitemid 32912430)
46. Quintana H, Birmaher B, Stedge D et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25:283-294.
47. Handen BL, Johnson CR, Lubetsky M. Effi cacy of methylphenidate among children with autism and symptoms of attention defi cit hyperactivity disorder. J Autism Dev Disord 2000; 30: 245-255.
48. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized controlled crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62:1266-1274.
49. Jou RJ, Handen BL, Harda AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15: 325-330. (Pubitemid 40734112)
50. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-defi cit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16:599-610. (Pubitemid 44739916)
51. Troost PW, Steenhuis MP, Tuynman-Qua HG. Atomoxetine for attention-defi cit hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006; 16:611-619. (Pubitemid 44737214)
52. Arnold LE, Aman MG, Cook AM et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled cross-over pilot trial. J Am Acad Child Adolesc Psychopharmacol 2006; 45:1196-1205.
53. Kerbeshian J, Burd L, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology . J Clin Psychopharmacol 1987; 7:401-405. (Pubitemid 18006087)
54. Steingard R, Biederman J. Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1987; 26:932-935. (Pubitemid 18010906)
55. Kapetanovic S. Oxcarbazepine in youths with autistic disorder and signifi cant disruptive behaviors. Am J Psychiatry 2007; 164:832-833. (Pubitemid 46808549)
56. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs placebo in the treatment of repetitive behaviors in autistic spectrum disorder. Int J Neuropsychopharmacol 2006; 9:209-213. (Pubitemid 43255834)
57. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autistic spectrum disorders. J Clin Psychiatry 2001; 62:530-534. (Pubitemid 32703092)
58. Hellings JA, Weckbaugh M, Nickel EJ e t al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15:682-692. (Pubitemid 41434372)
59. Campbell M, Overall JE, Small AM et al. Naltrexone in autistic children: an acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 1989; 28:200-206. (Pubitemid 19086187)
60. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child and Adolesc Psychiatry 1993; 32:1283-1291. (Pubitemid 23319191)
61. Kolmen BK, Feldman HM, Handen BL et al. Naltrexone in young autistic children: a double-blind placebo-controlled crossoverstudy. J Am Acad Child Adolesc Psychiatry 1995; 34:223-231.
62. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 1997; 36:1570-1578.
63. Feldman HM, Kolmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 1999; 38:587-593. (Pubitemid 29203475)
64. Willemsen-Swinkels SHN, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996; 39:1023-1031. (Pubitemid 26191350)
65. Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic Disorder. J Clin Psychopharmacol 1992; 12:322-327.
66. Fankhauser MP, Karamanchi VC, German MLEA. A double blind placebo-controlled study of the effi cacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53:77-82.
67. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004; 14:233-241.
68. Scahill L, Aman MG, McDougle CJ e t al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16:589-598. (Pubitemid 44737213)
69. King BH, Wright DM, Handen BL e t al. Double-blind, placebocontrolled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001; 40:658-665.
70. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorder. Psychopharmacol 2007; 191:141-147. (Pubitemid 46294942)
71. Owley T, Salt J, Guter S e t al. A prospective open-label trial of memantine in the treatment of cognitive, behavioral and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16:517-524. (Pubitemid 44737207)
72. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. J Child Neurol 2007; 22:574-579. (Pubitemid 46951501)
73. Wasdell MB, Jan JE, Bomben MM et al. A randomized, placebocontrolled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008; 44:57-64.
74. Paavonen EJ, Nieminen-von Wendt T, Vanhala R, Aronen ET, von Wendt L. Effectiveness of melatonin in the treatment of sleep disturbance in children with asperger disorder. J Child Adolesc Psychopharmacol 2003; 13:38-95. (Pubitemid 36570191)
75. Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord 2006; 36:741-752. (Pubitemid 44284978)
76. Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 2008; 23:482-485. (Pubitemid 351566859)
77. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems . Child Care Health Dev 2006; 32:585-589. (Pubitemid 44210097)
78. Hovath K, Stefanatos G, Sokolski K, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minority Physicians 1998; 9:9-15.
79. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev 2005; (3):CD003495.